Literature DB >> 30422433

Secondary lymphedema after head and neck cancer therapy: A review.

A Anand1, D Balasubramanian1, N Subramanian1, S Murthy1, S Limbachiya1, S Iyer2,1, K Thankappan1, M Sharma2.   

Abstract

Secondary head and neck lymphedema (SHNL) is a chronic condition affecting patients who have undergone treatment for head and neck cancers. It results from the disruption of normal lymphatic flow by surgery and/or radiation. The incidence of secondary head and neck lymphedema varies anywhere between 12 and 54% of all patients treated for head and neck cancer, but it is still commonly under-diagnosed in routine clinical practice. In spite of awareness of this condition, treatment has been difficult as definitive staging, diagnostic, and assessment tools are still under development. This review article is aimed at looking at the evidence, standards of management, and deficiencies in current literature related to SHNL to optimize management of these patients and improve their quality of life. Copyright by International Society of Lymphology.

Entities:  

Keywords:  CDT; MLD; cancer; diagnosis; head and neck lymphedema; imaging; quality-of-life; treatment

Mesh:

Year:  2018        PMID: 30422433

Source DB:  PubMed          Journal:  Lymphology        ISSN: 0024-7766            Impact factor:   1.286


  3 in total

1.  Edemas of the face and lymphoscintigraphic examination.

Authors:  Pierre Bourgeois; E Peters; A Van Mieghem; A Vrancken; G Giacalone; A Zeltzer
Journal:  Sci Rep       Date:  2021-03-19       Impact factor: 4.379

Review 2.  Healthcare Practitioners' Knowledge of Lymphedema.

Authors:  Hossein Yarmohammadi; Amirhossein Rooddehghan; Masood Soltanipur; Amirabbas Sarafraz; Seyed Fatah Mahdavi Anari
Journal:  Int J Vasc Med       Date:  2021-12-31

3.  Impact of free flap reconstruction on obstructive sleep apnea in patients with oral and oropharyngeal cancer.

Authors:  Fu-Hsin Liao; Chan-Chi Chang; Yu-Cheng Lu; Cheng-Yu Lin; Wei-Shu Lai
Journal:  Asia Pac J Oncol Nurs       Date:  2022-08-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.